Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF) announced management will participate in two virtual investor conferences on October 9, 2025. A Piper Sandler Virtual Oncology Symposium fireside chat will feature Mark Erlander, PhD (CEO), James Levine (CFO) and Roger Sidhu, MD (CMO) at 1:00 PM ET. A Noble Capital Markets Emerging Growth Virtual Equity Conference fireside chat will feature Mark Erlander at 2:00 PM ET.
Attendance instructions: contact Piper Sandler for access; Noble registration is free. A webcast replay will be posted within 48 hours in the Events section of Cardiff Oncology’s website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRDF gained 4.29%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025.
Details of the events can be found below.
Piper Sandler Virtual Oncology Symposium
Format: Fireside Chat
Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO)
Date: 10/09/2025
Time: 1:00 PM ET
Contact Piper Sandler for information on attending the conference.
Noble Capital Markets’ Emerging Growth Virtual Equity Conference
Format: Fireside Chat
Presenter: Mark Erlander, CEO
Date: 10/09/2025
Time: 2:00 PM ET
Interested parties can register for the Noble Capital Markets’ Emerging Growth Virtual Equity Conference at no cost here: Virtual Equity Conference Registration. The webcast replay will be available within 48 hours of the conclusion of the presentation on the “Events” section of the Cardiff Oncology website.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Meghan Bianco
Taft Communications, a division of RF|Binder
609-544-5446
meghan.bianco@rfbinder.com
FAQ
When will Cardiff Oncology (CRDF) present at investor conferences in October 2025?
Who will present for Cardiff Oncology (CRDF) at the Piper Sandler Virtual Oncology Symposium?
How can investors register for the Noble Capital Markets Emerging Growth Virtual Equity Conference for CRDF?
Will Cardiff Oncology (CRDF) make a replay available after the October 9, 2025 presentations?
What format will Cardiff Oncology's (CRDF) October 9, 2025 presentations follow?
Who should I contact to attend the Piper Sandler session where Cardiff Oncology (CRDF) presents?
